Background and Objective: Dill (Anethum graveolens L.) has the potential to develop as a new alternative medicine due to its pharmacological activities. However, studies into its safety regarding herb-drug interactions have been neglected. This study investigated the risk of dill-induced herb-drug interactions (HDI) by examining its effect on the expression of phase I and II drug-metabolizing enzyme and transporter genes in Caco-2 cells. Materials and Methods: Caco-2 cells (5×105 cells/well) were treated with 10 µM ketoconazole, 20 µM rifampicin or dill extract (60-240 µg mLG1) for 72 hrs. Cell viability was assessed using the resazurin assay and reactive oxygen species (ROS) content was determined with 2 ,7 -dichlorofluorescein diacetate. Aspartate (AST) and alanine aminotransferase (ALT) levels were measured using L-aspartate and L-alanine with "-ketoglutarate as substrate. Expression of phase I (CYP1A2, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) and II (UGT1A6, SULT1A1, NAT1, NAT2 and GSTA1/2) metabolizing genes and transporters (ABCB1, ABCC2, ABCG2 and SLCO1B1) were determined by RT/qPCR. Results: All tested concentrations of dill did not affect cell viability or AST and ALT levels. The highest concentration of dill extract (240 µg mLG1) significantly lowered the ROS level. Expression of CYP1A2, CYP2C19, SULT1A1, NAT2 and ABCB1 mRNA was significantly up-regulated by dill extract. Conclusion: Dill extract did not directly damage Caco-2 cells but prolonged use of dill may increase the risk of HDI via the up-regulation of the drug-metabolizing genes CYP1A2, CYP2C19, SULT1A1, NAT2 and the transporter ABCB1